PMID- 19298601
OWN - NLM
STAT- MEDLINE
DCOM- 20090604
LR  - 20090511
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 100
IP  - 5
DP  - 2009 May
TI  - Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 
      urothelial carcinoma of the bladder.
PG  - 896-902
LID - 10.1111/j.1349-7006.2009.01126.x [doi]
AB  - The authors investigated the status of abnormalities of eIF-5A2 gene in 
      superficial (pTa/pT1) urothelial carcinoma of the bladder (UC), as well as its 
      correlation with clinicopathologic variables and patient outcome. The methods of 
      immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), reverse 
      transcription-polymerase chain reaction (RT-PCR) and Western blotting were 
      utilized to examine protein/mRNA(messenger RNA) expression and amplification of 
      eIF-5A2 in a cohort of pTa/pT1 UCs. Overexpression of EIF-5A2 was examined by IHC 
      in 38/112 (33.9%) pTa/pT1 UCs. A significant association of overexpression of 
      EIF-5A2 with shortened UC patient recurrence-free survival (P = 0.002), as well 
      as with shortened progression-free survival (P = 0.004), was demonstrated. 
      Importantly, multivariate Cox regression analysis revealed that EIF-5A2 
      expression provided a significant independent prognostic parameter either in 
      tumor recurrence (P = 0.002) or in tumor progression (P = 0.007). FISH results 
      demonstrated that eIF-5A2 amplification was detected in 5/59 of the informative 
      UCs; in each of the five cases with eIF-5A2 amplification, overexpression of 
      EIF-5A2 was observed. In the remaining 54 UCs without eIF-5A2 amplification, 16 
      cases were also observed to have overexpression of EIF-5A2. In 13 pairs of UC and 
      adjacent normal tissues, eight UCs were examined and showed up-regulated eIF-5A2 
      mRNA by RT-PCR, while increased expression of EIF-5A2 protein was only detected 
      in 4/8 UCs by Western blotting. These findings suggest that overexpression of 
      EIF-5A2, as detected by IHC, may predict tumor recurrence and progression in 
      pTa/pT1 UC patients, and the protein expression of eIF-5A2 might be regulated not 
      only by gene amplification, but also by other molecular mechanisms.
FAU - Luo, Jun-Hang
AU  - Luo JH
AD  - The State Key Laboratory of Oncology in Southern China, Cancer Center, Sun 
      Yat-Sen University, Guangzhou 510060, China.
FAU - Hua, Wen-Feng
AU  - Hua WF
FAU - Rao, Hui-Lan
AU  - Rao HL
FAU - Liao, Yi-Ji
AU  - Liao YJ
FAU - Kung, Hsiang-Fu
AU  - Kung HF
FAU - Zeng, Yi-Xin
AU  - Zeng YX
FAU - Guan, Xin-Yuan
AU  - Guan XY
FAU - Chen, Wei
AU  - Chen W
FAU - Xie, Dan
AU  - Xie D
LA  - eng
PT  - Journal Article
DEP - 20090226
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Peptide Initiation Factors)
RN  - 0 (RNA, Messenger)
RN  - 0 (eIF-5A2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Peptide Initiation Factors/genetics/*metabolism
MH  - RNA, Messenger/genetics
MH  - Recurrence
MH  - Survival Rate
MH  - Urinary Bladder Neoplasms/*metabolism/*pathology
EDAT- 2009/03/21 09:00
MHDA- 2009/06/06 09:00
CRDT- 2009/03/21 09:00
PHST- 2009/03/21 09:00 [entrez]
PHST- 2009/03/21 09:00 [pubmed]
PHST- 2009/06/06 09:00 [medline]
AID - CAS1126 [pii]
AID - 10.1111/j.1349-7006.2009.01126.x [doi]
PST - ppublish
SO  - Cancer Sci. 2009 May;100(5):896-902. doi: 10.1111/j.1349-7006.2009.01126.x. Epub 
      2009 Feb 26.